IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

IMV Inc (IMV) formerly known as Immunovaccine Inc, is a clinical-stage immuno-oncology company that develops cancer immunotherapies and infectious disease vaccines. The company develops its products based on DepoVax platform, a vaccine adjuvant and delivery platform technology. Its immuno oncology pipeline products are intended for the treatment of ovarian, diffuse large B cell lymphoma (DLBCL) tumors and human papillomavirus (HPV) cervical cancer. IMVs infectious disease product candidates are intended for the treatment of respiratory syncytial virus, malaria and others. The company partners with various universities, research institutes and other vaccine development companies to develop its product candidates for applications in cancer and infectious diseases. IMV is headquartered in Halifax, Nova Scotia, Canada.

IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IMV Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
PCI Biotech Enters into Agreement with IMV 11
Immunovaccine Enters into Agreement with Incyte 12
Immunovaccine Enters into Agreement with University of Edinburgh 13
Immunovaccine Extends Partnership with UConn Health 14
Immunovaccine Expands Agreement with Leidos 15
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 16
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 17
Equity Offering 18
IMV Plans to Raise up to USD150 Million in Public Offering of Securities 18
Immunovaccine Raises USD11.6 Million in Public Offering of Shares 19
Immunovaccine Raises USD7.4 Million in Public Offering of Shares 20
Immunovaccine Raises USD6 Million in Private Placement of Shares 21
Immunovaccine Raises USD6.2 Million in Private placement of Units 22
Immunovaccine Raises USD8.7 Million in Public Offering of Units 24
Immunovaccine Raise USD1.58 Million in Private Placement of Shares 26
Immunovaccine Withdraws Prospectus For Public Offering Of Shares For US$6.8 Million 27
Immunovaccine Withdraws Private Placement Of Shares For US$1 Million 28
Immunovaccine Completes Private Placement Of Shares For US$4 Million 29
Immunovaccine Completes Private Placement Of Units For US$1.6 Million 30
Immunovaccine Completes Private Placement Of Common Stock For US$2.8 Million 32
IMV Inc - Key Competitors 33
IMV Inc - Key Employees 34
IMV Inc - Locations And Subsidiaries 35
Head Office 35
Recent Developments 36
Financial Announcements 36
May 14, 2018: IMV Announces Q1 2018 Financial Results 36
Mar 20, 2018: Immunovaccine Announces Year-End 2017 Financial Results 38
Nov 09, 2017: Immunovaccine Announces Third Quarter 2017 Financial Results 40
Aug 08, 2017: Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017 41
May 10, 2017: Immunovaccine Announces Financial Results for Quarter Ended March 31, 2017 43
Mar 30, 2017: Immunovaccine Announces 2016 Year-End Results 44
Corporate Communications 47
Jun 07, 2018: IMV Appoints Julia P. Gregory to Board of Directors 47
May 31, 2018: Nasdaq Approves Listing of IMV Common Shares 48
Jan 18, 2018: Immunovaccine Appoints Joseph Sullivan as Senior Vice President of Business Development 49
Feb 03, 2017: Immunovaccine Appoints Seasoned Financial Executive Pierre Labbe as CFO 50
Product News 51
Jan 31, 2018: Published Study Demonstrates the Association Between Immunovaccines Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression 51
Clinical Trials 52
Oct 05, 2017: Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Companys DepoVax-based Programs 52
Apr 12, 2017: Immunovaccine Announces Positive Year-Long Immunogenicity Data from Phase 1 Clinical Trial for Respiratory Syncytial Virus Vaccine Candidate 53
Other Significant Developments 54
May 10, 2018: IMV Change of ticker on OTCQX from IMMVF to IMMVD 54
Aug 08, 2017: Immunovaccine Issues Second Quarter 2017 Letter to Shareholders 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List Of Tables


IMV Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Deals By Therapy Area, 2012 to YTD 2018 9
IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PCI Biotech Enters into Agreement with IMV 11
Immunovaccine Enters into Agreement with Incyte 12
Immunovaccine Enters into Agreement with University of Edinburgh 13
Immunovaccine Extends Partnership with UConn Health 14
Immunovaccine Expands Agreement with Leidos 15
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 16
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 17
IMV Plans to Raise up to USD150 Million in Public Offering of Securities 18
Immunovaccine Raises USD11.6 Million in Public Offering of Shares 19
Immunovaccine Raises USD7.4 Million in Public Offering of Shares 20
Immunovaccine Raises USD6 Million in Private Placement of Shares 21
Immunovaccine Raises USD6.2 Million in Private placement of Units 22
Immunovaccine Raises USD8.7 Million in Public Offering of Units 24
Immunovaccine Raise USD1.58 Million in Private Placement of Shares 26
Immunovaccine Withdraws Prospectus For Public Offering Of Shares For US$6.8 Million 27
Immunovaccine Withdraws Private Placement Of Shares For US$1 Million 28
Immunovaccine Completes Private Placement Of Shares For US$4 Million 29
Immunovaccine Completes Private Placement Of Units For US$1.6 Million 30
Immunovaccine Completes Private Placement Of Common Stock For US$2.8 Million 32
IMV Inc, Key Competitors 33
IMV Inc, Key Employees 34

List Of Figures


IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

IMV Inc (IMV) formerly known as Immunovaccine Inc, is a clinical-stage immuno-oncology company that develops cancer immunotherapies and infectious disease vaccines. The company develops its products based on DepoVax platform,

USD 250 View Report

Imvest Strategic Analysis Review- Imvest SWOT, Outlook, Operations and Financial Profile

Imvest Company Profile provides strategic analysis of Imvest Company in current market conditions. The companys business/ operational/growth strategies are analyzed in the unique research work. Growth opportunities available for the

USD 200 View Report

Immunovaccine Inc (IMV) - Financial and Strategic SWOT Analysis Review

Immunovaccine Inc (IMV), formerly Rhino Resources Inc is a clinical-stage immuno-oncology company that develops cancer immunotherapies and infectious disease vaccines. The company develops its products based on DepoVax platform, a

USD 300 View Report

Immunovaccine Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Immunovaccine Inc (IMV), formerly Rhino Resources Inc is a clinical-stage immuno-oncology company that develops cancer immunotherapies and infectious disease vaccines. The company develops its products based on DepoVax platform, a

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available